Priya Sriskandarajah: Roginolisib Plus JAK Inhibitors in Myelofibrosis
Priya Sriskandarajah, Consultant Haematologist at Guy’s and St Thomas’ NHS Foundation Trust, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in OncoTargets and Therapy, adding:
”Do check out our paper just published in OncoTargets and Therapy which covers the ongoing Hema-MED trial combining JAK inhibitors with the PI3K inhibitor Rogilinosib in MF patients. Delighted to be running this study at Guy’s and St Thomas’ NHS.”
Title: Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) – A Trial in Progress
Authors: J Villarreal Hernandez, JOD Carbonero, C Paoli, P Guglielmelli, M Tiribelli, F Palandri, JM Hernandez-Rivas, ML Fox, DC García de la Torre, G Greenfield, C Rinaldi, P Sriskandarajah, C Harrison, F Pane, G Lanzarone, D Cilloni, M Pacilli, M Breccia, M Lahn, G Di Conza, TC Hammett, P Kaur, M Emig, KM Tonge, M Cantarini, J Polasek, A Lucchesi, A Santoro, AM Vannucchi
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 2, 2026, 18:34Kamini Khillan: Massive Transfusion Protocol for PPH Management
-
Oct 2, 2026, 18:24Garima Sharma։ GLP-1 Receptor Agonists Across the Reproductive Life Course
-
Oct 2, 2026, 17:40Chokri Ben Lamine: A Two-Day Journey Through Modern Hematology at KFSHRC
-
Oct 2, 2026, 17:27Reza Shojaei: The Invisible Crisis, Part 1- Donor Deferral in Whole Blood
-
Oct 2, 2026, 16:02Advancing Antithrombotic Stewardship to Optimise Care – American Heart Association
-
Oct 2, 2026, 15:37Pall T. Onundarson: Monitoring Warfarin Beyond Factor VII
-
Oct 2, 2026, 15:26Nicola Carter: World Thrombosis Day Highlights Gender Specific Risks and Prevention
-
Oct 2, 2026, 14:56Wolfgang Miesbach: Direct Comparison Reveals Distinct Mechanisms Among FVIIIa Mimetics
-
Oct 2, 2026, 14:47Strengthening Hemophilia Care Through Advocacy and Partnership – World Federation of Hemophilia